Unions and health insurers cannot pursue a nationwide class action consumer fraud case for billions of dollars spent on the painkiller Vioxx, the New Jersey Supreme Court says.

The justices on Thursday reversed lower court rulings that certified the suit by third-party payers against Merck & Co. Inc., which sold the painkiller from 1999 until withdrawing it from the market in 2004.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]